BioSpecifics Reports Positive Top-line Data From Phase 2 Trial Of CCH

(RTTNews) - BioSpecifics Technologies Corp. (BSTC) announced top-line data from the Phase 2 dose escalation clinical trial of collagenase clostridium histolyticum for the treatment of human lipoma. The company reported that the primary efficacy outcome of active reduction of the visible surface area of the lipoma as measured by caliper was met, combining all patients. There were no serious adverse events reported during the trial.

BioSpecifics' strategic partner Auxilium Pharmaceuticals, Inc. (AUXL) has the option to exclusively license development and marketing rights to the human lipoma indication following completion of a new trial, which would trigger an opt-in payment and potential future milestone and royalty payments from Auxilium.

BioSpecifics intends to initiate a placebo-controlled study to further assess the efficacy and safety of collagenase clostridium histolyticum for the treatment of human lipoma in the first half of 2014.